{'text': 'Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple Myeloma Who Have Received One to Three Prior Therapies', 'publisher': {'href': 'https://www.businesswire.com', 'title': 'Business Wire'}, 'created_at': 'Mon, 30 Nov 2015 08:00:00 GMT', 'description': 'Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple Myeloma Who Have Received One to Three Prior Therapies  Business Wire', 'url': 'https://news.google.com/rss/articles/CBMi3gJBVV95cUxPblB5MUhrMkxzTGxybVJDZl9MTFB4UW1ubVdxTTd6TFgyMEFKNjc5RVYzeDJ5WFJSMGV2VnNJMjNHSHMyT2RZbnNQS2w0QlBnQlRrNHpMTnRrN0FhR2tBMWQ0clRNdGpUeWw2Ti1YNnI2NklLNHl6dDZHeVZjaGRuaWNFMXFseWdrTTl5Sm9oOURDb0l4TjkxYTdNYTlrZ3FJRFJGU3FPRHRydVI3MWd0WHBOZ0c0Ui1MQ0NDLThJdkp2dGhjaVRSemNVU1FtY29LVEJxSFpFNWVnQXlrYnZjMzZiVkNacnVQbzFNZUIyZDJtNXVjNE9IOUFXb2l5US1LdzRPQTFnVU0zTW1FS0ZhdmZSQUV1ZWtSN3BmbTdSVUVlODc0QTNSbTZ3NGNydWJsMGc5N1Y0eHFSdldQaUp0Yk56X0FoM1hURWM4blUzU2tjX2VsaDI3YWRkeUZCdw?oc=5&hl=en-SG&gl=SG&ceid=SG:en'}
